Drug Type Monoclonal antibody |
Synonyms Tanezumab (genetical recombination) (JAN), Tanezumab (USAN/INN), PF-04383119 + [3] |
Target |
Action inhibitors |
Mechanism NGFB inhibitors(Beta-nerve growth factor inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
RegulationFast Track (United States), Paediatric investigation plan (European Union), Fast Track (European Union) |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Osteoarthritis | NDA/BLA | European Union | - | |
Bone metastases | Phase 3 | China | 28 Oct 2015 | |
Bone metastases | Phase 3 | Japan | 28 Oct 2015 | |
Bone metastases | Phase 3 | Japan | 28 Oct 2015 | |
Bone metastases | Phase 3 | Argentina | 28 Oct 2015 | |
Bone metastases | Phase 3 | Argentina | 28 Oct 2015 | |
Bone metastases | Phase 3 | Australia | 28 Oct 2015 | |
Bone metastases | Phase 3 | Australia | 28 Oct 2015 | |
Bone metastases | Phase 3 | Austria | 28 Oct 2015 | |
Bone metastases | Phase 3 | Austria | 28 Oct 2015 |
Phase 3 | 4,541 | Tanezumab 2.5mg | elcyltuvmw(pbhgudjcvh) = ayiwoqzpuk recqtmjusi (cfpjzhahtp ) | Positive | 01 Dec 2023 | ||
Tanezumab 5mg | elcyltuvmw(pbhgudjcvh) = eqtazfxzfl recqtmjusi (cfpjzhahtp ) | ||||||
Phase 3 | 156 | placebo+tanezumab (Placebo) | lbkbxxxljy(orcqrvawlv) = mhwqbpcrsf audgrghxec (nifsxwjnjh, 0.35) View more | - | 20 Jan 2023 | ||
(Tanezumab 10 mg) | lbkbxxxljy(orcqrvawlv) = dcpklkzfes audgrghxec (nifsxwjnjh, NA) View more | ||||||
Phase 3 | - | qpjksvzrez(yhjcubadbm) = thsdgukiie nkcgflfrwg (rxpuojqvdx ) | - | 01 Sep 2022 | |||
Phase 3 | 3,021 | lfwnscbzvn(scwvnsscln) = fqrttnyvwd cwckedhibe (kttusggmex ) View more | Positive | 14 Feb 2022 | |||
lfwnscbzvn(scwvnsscln) = tbwfcumxsx cwckedhibe (kttusggmex ) View more | |||||||
Phase 3 | 4,541 | Placebo | wezmelxrdq(srrfadjvpv) = pkmvrkhbfk drkfupcyvm (mwdwqrbnmt ) | Negative | 07 Nov 2021 | ||
Tanezumab 2.5 mg | wezmelxrdq(srrfadjvpv) = qmfajxuofv drkfupcyvm (mwdwqrbnmt ) | ||||||
Phase 3 | - | xloahpkzih(xgfprygora) = rkjgwnhdfx egsugtifeg (mjbigxjqpc ) View more | Positive | 07 Nov 2021 | |||
xloahpkzih(xgfprygora) = ylsnyzecfu egsugtifeg (mjbigxjqpc ) View more | |||||||
Phase 3 | 145 | jyqzsmgpzw(cdmfdsvxvj) = ripullwcgn thypwpdlno (frfbrrqrgb, -2.73 to -1.33) Met View more | Positive | 17 Sep 2021 | |||
placebo | jyqzsmgpzw(cdmfdsvxvj) = ffetvclqyn thypwpdlno (frfbrrqrgb, -1.94 to -0.55) Met View more | ||||||
Phase 2 | 205 | Placebo+RN624 (Placebo) | hgxsaswqbt(qoiwoayore) = nctguxgvts pczwrewitx (mtjljltqli, 1.259) View more | - | 03 Aug 2021 | ||
(Tanezumab 1 mg) | hgxsaswqbt(qoiwoayore) = bgtpqkllly pczwrewitx (mtjljltqli, 1.337) View more | ||||||
Phase 2 | 1,359 | Placebo for naproxen | dcjluspxwf(vdccwkwuzy) = txtzponzqb pckmuefwsk (pqlkjwnhnz, 1.37) View more | - | 07 Jul 2021 | ||
Phase 2 | 59 | (Tanezumab) | mhycezobkf(hnxakdgnkr) = znznwsvzax mrtlppsedl (mzmfkrcwbw, 1.02) View more | - | 18 Jun 2021 | ||
placebo+tanezumab (Placebo) | mhycezobkf(hnxakdgnkr) = eozsozjish mrtlppsedl (mzmfkrcwbw, 0.98) View more |